The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
The partnership will capitalize on the combined capabilities of the two organizations
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Subscribe To Our Newsletter & Stay Updated
